Tata backed Impetis licenses new selective JAK drugs for arthritis and hair thinning to Vyome

Published on 13 May 2026

Selective inhibitors aim to reduce risks from earlier JAKs

Impetis Biosciences, a Tata group subsidiary, has partnered with US based Vyome Holdings to license two experimental selective JAK inhibitors. The therapies target rheumatoid arthritis and hair thinning while being designed to lower safety risks seen with earlier JAK treatments, marking a notable push toward refined, risk aware drug development.

Impetis Biosciences, part of Tata group, licensed two experimental drugs
Partnership with US firm Vyome Holdings for selective JAK inhibitors
Targets rheumatoid arthritis and hair thinning therapies
Design focuses on reducing risks linked to older JAK treatments

#tata group #imp etis biosciences #jak inhibitors #rheumatoid arthritis #drug licensing

Read the full story at The Economic Times

This summarization was done by Beige for a story published on The Economic Times

Tata backed Impetis licenses new selective JAK drugs for arthritis and hair thinning to Vyome

The full experience is on mobile.